Athira Pharma, Inc. (NASDAQ:ATHA) Short Interest Update

Athira Pharma, Inc. (NASDAQ:ATHA) saw a significant decrease in short interest in August. As of August 31st, there was short interest totalling 823,500 shares, a decrease of 17.3% from the August 15th total of 996,000 shares. Based on an average daily volume of 239,000 shares, the short-interest ratio is presently 3.4 days. Approximately 2.3% of the company’s shares are sold short.

Hedge Funds Weigh In On Athira Pharma

Institutional investors and hedge funds have recently modified their holdings of the company. Simplify Asset Management Inc. purchased a new stake in shares of Athira Pharma during the 1st quarter worth approximately $3,475,000. BML Capital Management LLC grew its holdings in shares of Athira Pharma by 160.9% during the first quarter. BML Capital Management LLC now owns 1,864,907 shares of the company’s stock worth $4,662,000 after purchasing an additional 1,150,144 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Athira Pharma during the second quarter worth about $2,671,000. Tang Capital Management LLC acquired a new stake in shares of Athira Pharma during the fourth quarter worth about $1,538,000. Finally, Baker BROS. Advisors LP lifted its holdings in shares of Athira Pharma by 25.0% in the 1st quarter. Baker BROS. Advisors LP now owns 2,350,355 shares of the company’s stock valued at $5,876,000 after purchasing an additional 470,519 shares during the last quarter. Institutional investors and hedge funds own 62.74% of the company’s stock.

Athira Pharma Stock Up 1.5 %

Shares of Athira Pharma stock traded up $0.03 during trading hours on Tuesday, reaching $1.98. 43,792 shares of the company were exchanged, compared to its average volume of 255,327. The stock’s fifty day moving average is $2.63 and its 200 day moving average is $2.74. Athira Pharma has a 1 year low of $1.94 and a 1 year high of $4.41.

Athira Pharma (NASDAQ:ATHA) last released its earnings results on Thursday, August 10th. The company reported ($0.78) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.03. As a group, equities analysts expect that Athira Pharma will post -3.31 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, JMP Securities decreased their target price on Athira Pharma from $20.00 to $19.00 and set an “outperform” rating on the stock in a research note on Friday, August 11th.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is ATH-1017 Fosgonimeton, a small molecule designed to enhance the activity of hepatocyte growth factor (HGF) and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease.